ReviewClinical pharmacology and therapeutics2008
Hormonal regulation of hepatic drug-metabolizing enzyme activity during adolescence.
Review in Clinical pharmacology and therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 92 citations in OpenAlex.
- Ontogeny and sorafenib metabolism.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Trial
- Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism.npj biomedical innovations · 2026Review
- Hepatic CYP1A2 Activity in Adolescents with and without Obesity Assessed by the Urinary Paraxanthine-to-Caffeine Metabolic Ratio: A Pharmacokinetic Study.Journal of clinical pharmacology · 2026Article
- Medication adherence in adolescents: physiological, psychosocial, and clinical perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Biological sex differences in pharmacokinetics and adverse drug reactions.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Tacrolimus Pharmacokinetics in Pediatric Liver Transplant Recipients During the First Month After Transplantation.European journal of drug metabolism and pharmacokinetics · 2026Article
- Tobacco smoking as an endocrine disrupting chemical: An assessment through biological monitoring.Tobacco induced diseases · 2025Article
- Clinical pharmacology in adolescent transgender medicine.British journal of clinical pharmacology · 2024Review
- Pharmacokinetic-Pharmacodynamic Modeling of Midazolam in Pediatric Surgery.Pharmaceutics · 2023Article
- Influence of Age and Sex on the Pharmacokinetics of Midazolam and the Depth of Sedation in Pediatric Patients Undergoing Minor Surgeries.Pharmaceutics · 2023Article
- Current knowledge, challenges and innovations in developmental pharmacology: A combined conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper.British journal of clinical pharmacology · 2022Review
- A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development.Med (New York, N.Y.) · 2022Article
- No population left behind: Improving paediatric drug safety using informatics and systems biology.British journal of clinical pharmacology · 2022Review
- Retrospective Review of Clozapine Use in Children and Adolescents.Journal of the Canadian Academy of Child and Adolescent Psychiatry = Journal de l'Academie canadienne de psychiatrie de l'enfant et de l'adolescent · 2021Article
- Hepatic Cytochrome P450 Abundance and Activity in the Developing and Adult Göttingen Minipig: Pivotal Data for PBPK Modeling.Frontiers in pharmacology · 2021Article
- Review
- Article
- The clinical toxicology of caffeine: A review and case study.Toxicology reports · 2018Review
- Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus.Clinical pharmacokinetics · 2017Review
- Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.British journal of clinical pharmacology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Activities of drug-metabolizing enzymes (DMEs) are known to change throughout the course of physical and sexual maturation, with the greatest variability noted during infancy and adolescence. The mechanisms responsible for developmental regulation of DME are currently unknown. However, the hormonal changes associated with puberty/adolescence provide a theoretical framework for understanding the biochemical regulation of DME activity during growth and maturation. Important information regarding potential influences of growth and sex hormones can also be extrapolated from studies that evaluate changes in activities of DMEs occurring as a consequence of physiological, pathological, and/or pharmacological hormonal fluctuations. Collectively, current data support the hypothesis that isoform-specific alterations in DME activity during adolescence are mediated by sex and/or growth hormones. Characterization of the underlying biochemical alterations responsible for developmental changes in DME activity will require additional studies in which relationships between DMEs and important hormonal axes are evaluated during the course of pubertal development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.